Latest news with #drugtesting
Globe and Mail
20 hours ago
- Business
- Globe and Mail
Intelligent Bio Solutions (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25
The company's non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates. Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings. INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity. The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety. INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies ( The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for… Read More>> NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
Irish Times
a day ago
- Politics
- Irish Times
Regulations due this year to enable mandatory drug testing for gardaí
Regulations to allow for the mandatory drug testing of gardaí are expected to be in force before the end of the year, the Department of Justice has said. Testing was originally due to be introduced before the end of 2021. Officials from the department are working with An Garda Síochána and drafters within the Office of the Attorney General to finalise the regulations that will underpin the roll-out of drug testing across the force. 'The regulations are complex, will require thorough consideration and remain subject to legal advice, but it is hoped that they will be in place before the end of the year,' a spokesman for the department said. READ MORE 'The general roll out of testing will be a matter for An Garda Síochána once the regulations are in place.' The Policing, Security and Community Safety Act 2024 was signed into law more than a year ago and contains provisions that will allow for the roll-out of substance misuse testing in An Garda Síochána. 'The Act includes provision for regulations that will provide a detailed framework as to how exactly this testing will be carried out,' the spokesman said. The department said substance misuse testing as part of recruitment competitions has already been introduced, with applicants required to pass. An Garda Síochána said that once the regulations are introduced it will conduct a legal assessment and establish the necessary procedural framework. 'Such testing is standard practice across international police services, the Defence Forces, and various high-risk industries,' a Garda spokeswoman said. 'If the presence of a controlled drug is attributable to prescribed or other legitimate medication, a Medical Review Officer will confirm a negative test result. If no such explanation is available, An Garda Síochána will be advised of a positive test result, including details of the identified substances.' It was announced in June 2021 that the Anti-Corruption Unit would focus on drug use within the Garda as well as issues relating to professional boundaries and the abuse of power for sexual gain. Assistant Commissioner Pat Clavin said: 'We know of instances where we've had some of our people recreationally using drugs, so I would be concerned about the level of drug-taking in Irish society in general, and as I say our people come from Irish society.' The Department of Justice said the Garda Anti-Corruption Unit's Substance Misuse (Controlled Drugs) Policy 'ensures all Garda personnel are aware of their obligation to be fit to carry out their duties safely and effectively'. The policy says the misuse of controlled drugs by Garda personnel is not tolerated,and testing will be introduced to 'prevent and deter their use and identify individuals using such controlled drugs'.
Yahoo
5 days ago
- Business
- Yahoo
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the 'Company or Cannabix') reports that Omega Laboratories Inc. of Ohio, USA ('Omega Laboratories' or 'Omega') a leading drug testing laboratory renowned for its comprehensive services has delivered a Validation Packet for Omega's Laboratory Developed Test Method to test delta9 THC analytes in relation to the Cannabix Marijuana Breath Test ('MBT') technology (Figure 1). The Validation Packet was performed in Omega's ISO/IEC 17025 accredited laboratory environment following their Quality Management System. This validation included a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix Technologies' Breath Collection Unit (BCU) and Breath Cartridges (BC). The delivery of the Validation Packet completes a major milestone under the strategic partnership and development agreement ('SPDA') between Cannabix and Omega. This establishes Omega and Cannabix as the premier technology for collecting and testing breath for recent marijuana usage. Cannabix's MBT is a lab-based, collect and send solution, focused on 'recent use' detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption). (1) Omega Laboratories is an international industry leader in forensic drugs of abuse testing for over twenty years. Omega has multiple federal as well as international certifications and accreditations for its world class facility and has extensive experience in novel technology for detection of drugs of abuse. Cannabix and Omega are moving quickly to launch with select key clients and ramping up commercialization efforts for the Marijuana Breath Test. Omega Laboratories is currently integrating breath testing using Cannabix Breath Cartridges into its suite of services and testing protocols. Among various initiatives underway the Company and Omega are working together on marketing, distribution, support, manufacturing and logistics for the 1. Cannabix Marijuana Breath Test (BCU and Breath Cartridge) Under the SPDA, in consideration for the completion and delivery of the Validation Packet by Omega, the Company will convert 3 million Special Warrants into Special Warrant Shares to Omega. Furthermore, Omega will have the right to appoint one person to the board of directors of the Company in due course. (1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104. About Omega Laboratories, Inc. Omega Laboratories, headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Ontario, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 24 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine and Breath specimens. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless Custody & Control Form system (oCCF) in fourteen languages, licensure of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers new laboratories in countries that have demand for local service providers. About Cannabix Technologies Inc. Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring We seek Safe Harbor. On behalf of the Board of Directors 'Rav Mlait' CEOCannabix Technologies Inc. For further information, contact the Company at The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking StatementsThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company's development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any 'patent pending' or 'provisional patents' technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements. A photo accompanying this announcement is available at in to access your portfolio
News.com.au
5 days ago
- Health
- News.com.au
Sydney plastic surgeon, Dr Tobias Pincock, blames shocking drug test result on bagels
A scandal-plagued Sydney surgeon has once again been hauled in front of medical authorities, this time after testing positive for a slew of illicit drugs. Dr Tobias Pincock, throughout his career as a plastic surgeon, has been found to have performed a nose job on a patient 45 minutes after they suffered a cardiac arrest, losing $500,000 of his patient's money after convincing them to invest in a fund he majority-owned, and now getting done for being on illicit drugs while working. Australia's medical regulator, the Health Care Complaints Commission (HCCC), on Tuesday released its findings from a tribunal held in late 2024, which investigated a complaint against Dr Pincock. The complaint alleged that Dr Pincock breached the conditions on his registration by 'testing positive for illicit drugs, failing to attend drug screening on a number of occasions, providing a number of dilute urine samples' and 'failing to attend for treatment and monitoring.' Due to past positive tests, Dr Pincock was required to undertake periodic as well as random drug testing, but throughout the testing, Dr Pincock tested positive for cocaine, Endone, Temazepam, Endep, quetiapine, lignocaine, oxycodone, morphine, codeine, opiates and benzodiazepines. Dr Pincock provided the tribunal with many explanations for these positive results. Urinary drug testing on 13 January 2020 and 18 May 2022 indicated Dr Pincock had self-administered an amphetamine and an opioid, respectively. Dr Pincock claimed that he had either eaten several poppy seed bagels on the day of testing or the previous day, and that this was possibly the cause of a false positive result. However, the HCCC found 'at a time after (Dr Pincock) was tested on 18 May 2022, he photographed a packet of bagels, a toaster and a knife and sent that photo to the Medical Council. 'It is clear that this photo was not taken at the time the bagels were eaten but at the time he sent the photograph to the Medical Council, and tolerably clear that the practitioner, in effect, re-set the scene from earlier by posing the bagels with the toaster etc.' In his statement to the tribunal, Dr Pincock said he had not 'intentionally acted to be in breach of his conditions', yet the tribunal found on several occasions 'that is exactly what he did'. Dr Pincock came to the notice of medical regulators in 2016 when a complaint was made which alleged that he had used nitrous oxide recreationally. During an assessment by Dr Robert Fisher, Dr Pincock allegedly admitted to self-administering nitrous oxide to manage a panic attack. This was far from Dr Pincock's first brush with medical authorities. In 2011, Dr Pincock was 'reprimanded in the strongest terms' by a medical committee for performing a nose job on a patient 45 minutes after they had suffered a cardiac arrest. The patient required resuscitation and three defibrillations yet Dr Pincock allegedly felt that the patient would be 'disappointed' if the surgery didn't happen and 'might be reluctant to try again at a later date.' In 2018, Dr Pincock was also charged with the alleged assault of a 10-year-old boy and handed an apprehended violence order to stay away from the child. In January, Dr Pincock was found guilty of professional misconduct and barred from practising medicine for 18 months after encouraging two patients to invest over $500,000 into a trust he majority owned. The HCCC alleged that in 2015, Dr Pincock encouraged one of his patients to invest $335,000 into the 'Australian Allergy Centre' trust while both still employing her and continuing the doctor-patient relationship. The patient alleged Dr Pincock made the representation that 'the investment would mean that her children with disabilities would be financially taken care of for life and that the return on her investment would be $5,000,000 in five years.' The Civil and Administrative Tribunal of NSW (NCAT) found that 'Dr Pincock did not know, even in general terms, how much the [clinic] business was worth or would be worth in five years' time.' Dr Pincock is currently barred from practising medicine until mid-2026 as a result of earlier findings. Orders from his latest tribunal hearing render him unable to re-register as a clinician for 9 months, which will expire within the timeframe of his earlier orders. Dr Pincock charged with any criminal wrongdoing in relation to what was raised in the HCCC proceedings.
The Independent
7 days ago
- Health
- The Independent
Warning over synthetic opioid in blue-green pills linked to London nightclub deaths
Two people in their twenties have died in London after allegedly consuming a super-strong opioid drug, believed to be a nitazene, which can be hundreds of times stronger than heroin. The victims, a 20-year-old woman and a 28-year-old man, reportedly took the drug after visiting a club in south London over the May bank holiday weekend. Nightclub the Ministry of Sound issued a warning about blue-green pills marked with '80' being sold across London, which are suspected to contain synthetic opioids, ketamine, and MDMA, and are being mis-sold as ecstasy or oxycodone. Professor Fiona Measham, founder of drug checking charity The Loop, told The Times there had been two nitazene-related deaths per week in the UK, with the latest deaths appearing to leap from dependent to recreational users. The Metropolitan Police are investigating the deaths and awaiting toxicology results, while the Home Office stated they are working to tackle the threat from synthetic opioids but cannot endorse recreational drug testing.
